NCT01015495

Ranibizumab Therapy for Choroidal Neovascularization (CNV) Asociated With Angioid Streaks

Ranibizumab Therapy for Choroidal Neovascularization Associated With Angioid Streaks

• Status: Withdrawn
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: University of Illinois at Chicago · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to determine whether injections of ranibizumab into the eye are safe and well tolerated when given to subjects in multiple doses.

Detailed description

Choroidal neovascularization is a hallmark of angioid streaks, and presumably VEGF-driven. Ranibizumab has been shown to be effective in CNV secondary to age-related macular degeneration. Therefore, we hypothesize that ranibizumab may be efficacious in the treatment of CNV secondary to angioid streaks

Conditions

• Angioid Streaks

Interventions

Type	Name	Description
DRUG	ranibizumab	0.5 mg dose of ranibizumab. Treatment will be given at baseline, month 1, and month 2, and then monthly until OCT shows absence of subretinal fluid and FA shows absence of leakage

Timeline

• Start date: 2009-12-01
• Primary completion: 2010-12-01
• Completion: 2011-01-01
• First posted: 2009-11-18
• Last updated: 2012-07-02